Associated Balance of Risk Score – Comprehensive Complication Index for the Prediction of Post-transplant Survival

Overview

In recent years, several scoring systems have been developed aimed at predicting early post-LT graft function. However, many of them showed poor efficacy when long-term survivals were tested. Moreover, the necessity to find an easy-to-use score represents another obstacle, with several scores composed by numerous, difficult to find, variables. Recently, the pre-LT Balance of Risk (BAR) and the post-LT Comprehensive Complication Index (CCI) have been created, but their external validation and integration in this setting is lacking. This study aims at constructing an easy-to-use score system based on the combination of a small number of pre- and immediately post-liver transplant (LT) independent variables, in order to accurately predict long-term graft survival after LT.

Full Title of Study: “Associated Balance of Risk Score – Comprehensive Complication Index for the Prediction of Long-term Survival After Liver Transplantation”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: October 15, 2018

Detailed Description

In the last years, several scoring systems have been developed with the intent to predict waiting-list mortality or early allograft dysfunction (EAD) after liver transplantation (LT). The Model for End-stage Liver Disease (MELD) is recognised as the most accurate liver allograft allocation model by prioritising patients according to the severity of their disease. However, several studies showed that MELD alone failed to predict early and late post-transplant clinical course. Consequently, other scoring systems based on pre-LT or post-LT variables have been developed, with the intent to identify high-risk cases for death, graft loss or re-transplantation (re-LT). Among them, two pre-LT scores, namely the D-MELD and Balance of Risk (BAR), showed to well predict early post-LT survival. Similarly, some post-LT scores were able to estimate EAD, and, thereby, to predict the probabilities of early re-LT and patient death. Interestingly, all of these scores, especially those based on pre-LT variables, resulted in a scarce prediction of long-term (five-year) survivals. Recently, the Comprehensive Complication Index (CCI) has been developed in order to better capture complication rates after surgery. Some reports reported its excellent prognostic ability in different fields. However, up to now, no studies investigated the role of CCI concerning long-term prognostication of graft loss in LT. This study aims at constructing an easy-to-use score system based on the combination of a small number of pre- and immediately post-LT independent variables, in order to accurately predict five-year post-LT graft survival. Both external and internal validations of the score were performed.

Interventions

  • Procedure: Liver transplantation
    • First deceased-donor liver transplantation

Arms, Groups and Cohorts

  • Training liver transplantation
    • Patients consecutively transplanted in four European collaborative LT Centres (Ancona, Brussels, Rome Sapienza, and Padua) (N=1,262)
  • Validation liver transplantation
    • Patients consecutively transplanted in the Karolinska Institute (N=520)

Clinical Trial Outcome Measures

Primary Measures

  • Five-year post-transplant graft survival
    • Time Frame: 5 years
    • Number of participants experiencing a graft loss for any reason

Secondary Measures

  • Re-transplant rate
    • Time Frame: 5 years
    • Number of participants experiencing a re-transplant for any reason

Participating in This Clinical Trial

Inclusion Criteria

  • First transplant – adult (>18 years) Exclusion Criteria:

  • living donation – re-transplant – combined transplant – domino transplant – paediatric transplant

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • European Hepatocellular Cancer Liver Transplant Group
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Quirino Lai, MD PhD, Principal Investigator, UCL Brussels

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.